secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001193125-24-068170
Event type: regulatory
Sentiment:  positive
Materiality: 1.00
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal receives FDA accelerated approval for Rezdiffra, first NASH therapy
----------------------------------------------------------------------------

- FDA grants accelerated approval for Rezdiffra in NASH with F2-F3 fibrosis; first approved therapy for NASH.
- Approval based on Phase 3 MAESTRO-NASH: improved fibrosis and NASH resolution at 52 weeks vs placebo.
- Prescribing info does not require liver biopsy; weight-based dosing (80mg <100kg, 100mg >=100kg).
- Rezdiffra expected available in US in April via specialty pharmacy; patient support programs.
- Most common adverse reactions: diarrhea, nausea, pruritus, abdominal pain. Continued approval contingent on confirmatory outcomes data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524068170/0001193125-24-068170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524068170/d788116d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-068170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer